Eledon pharmaceuticals to participate in 18th annual noble capital markets investor conference

Irvine, calif., april 18, 2022 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that steve perrin, ph.d., president and chief scientific officer, will present at noblecon18, noble capital markets' eighteenth annual investor conference on thursday, april 21st  at 11:30 a.m. et.
ELDN Ratings Summary
ELDN Quant Ranking